EuropeEurope.portalSvet.Slajder

EU executive approves contract with Novavax for potential new vaccine

The European Commission has approved a contract for up to 200 million doses of Covid-19 vaccine with US pharmaceutical company Novavax, it announced on Wednesday.

The European Commission has approved a contract for up to 200 million doses of Covid-19 vaccine with US pharmaceutical company Novavax, it announced on Wednesday.

The vaccine will still have to be approved by the European Medicines Agency (EMA) before it can be distributed to and used in the 27 EU member states.

“As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,” European Commission President Ursula von der Leyen said in a press release.

The commission signs contracts on behalf of the member states, which can procure vaccine doses according to a distribution key that takes their population size into account.

Under the contract, EU countries can buy up to 100 million doses of the Novavax jabs, and sets out the option to buy an additional 100 million doses later.

After BioNTech/Pfizer, AstraZeneca, Sanofi, Johnson and Johnson, CureVac and Moderna, it is the seventh such contract the commission has approved.

This contract should ensure that the bloc has enough vaccine doses also at the end of this year and in 2022, the commission said.

More than half a billion doses of vaccines have been distributed to member states so far, according to the European Centre for Disease Prevention and Control.

Back to top button
Close